Ahl Masr Burn Hospital Concludes First Scientific Forum, Prepares for Expanded Second Edition in 2026    Egypt Tax Authority Standardises VAT Treatment for Exported Services, Issues Guidance    EGX ends week in green on 27 Nov.    Resilience, Innovation, and the Smart Home: Mohamed Ataya on GROHE's Strategic Vision for Egypt    Australia returns 17 rare ancient Egyptian artefacts    Asian stocks rise on Thursday    Oil prices dip on Thursday    Gaza death toll rises as humanitarian crisis deepens, Israeli offensive expands in West Bank    China's WINPEX to establish $15m lighting equipment plant in Ain Sokhna    Egypt expands rollout of Universal Health Insurance    Egypt's Al-Sisi links national progress to strict law enforcement, says society has role in reforming legal application    Cairo affirms commitment to Lebanese sovereignty, urges halt to cross-border violations    China invites Egypt to join African duty-free export scheme    Egypt, Algeria agree to deepen strategic ties, coordinate on Gaza ceasefire, regional crises    Egypt calls for stronger Africa-Europe partnership at Luanda summit    Egypt begins 2nd round of parliamentary elections with 34.6m eligible voters    Egypt warns of erratic Ethiopian dam operations after sharp swings in Blue Nile flows    Egypt scraps parliamentary election results in 19 districts over violations    Egypt extends Ramses II Tokyo Exhibition as it draws 350k visitors to date    Egypt signs host agreement for Barcelona Convention COP24 in December    Al-Sisi urges probe into election events, says vote could be cancelled if necessary    Filmmakers, experts to discuss teen mental health at Cairo festival panel    Cairo International Film Festival to premiere 'Malaga Alley,' honour Khaled El Nabawy    Cairo hosts African Union's 5th Awareness Week on Post-Conflict Reconstruction on 19 Nov.    Egypt golf team reclaims Arab standing with silver; Omar Hisham Talaat congratulates team    Egypt launches National Strategy for Rare Diseases at PHDC'25    Egypt adds trachoma elimination to health success track record: WHO    Grand Egyptian Museum welcomes over 12,000 visitors on seventh day    'Royalty on the Nile': Grand Ball of Monte-Carlo comes to Cairo    Egypt launches Red Sea Open to boost tourism, international profile    Omar Hisham Talaat: Media partnership with 'On Sports' key to promoting Egyptian golf tourism    Sisi expands national support fund to include diplomats who died on duty    Egypt's PM reviews efforts to remove Nile River encroachments    Egypt resolves dispute between top African sports bodies ahead of 2027 African Games    Germany among EU's priciest labour markets – official data    Paris Olympic gold '24 medals hit record value    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Russia says it's in sync with US, China, Pakistan on Taliban    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Britain nears $625 mln Sanofi/GSK COVID-19 vaccine deal -report
Published in Ahram Online on 05 - 07 - 2020

Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of a potential COVID-19 vaccine, the Sunday Times reported.
Clinical trials are due to start in September and Sanofi has said it expects to get approval by the first half of next year, sooner than previously anticipated.
More than 100 vaccines are being developed and tested around the world to stop the COVID-19 pandemic and governments are racing to secure supplies of vaccines even before their efficacy is proven.
A supply agreement with Sanofi and GSK would be Britain's second such deal, after it said it would buy 100 million doses of the Oxford-AstraZeneca vaccine.
Sanofi was not immediately available to comment, while a spokesman for GSK declined to comment. Both have both said they are prioritising quality over speed in developing a vaccine.
"The Government's Vaccines Task Force is actively engaging with a wide range of companies both in the UK and abroad to negotiate access to vaccines," a spokeswoman for Britain's business ministry, said, without confirming if Sanofi or GSK were among them.
The Sunday Times report said that Britain was considering taking an option to buy the vaccine should it work in human trials, and would see the amount paid in stages.
Sanofi is working on two possible COVID-19 vaccines, one of which uses an adjuvant made by GSK to potentially boost its efficacy, and has said it has capacity to produce up to 1 billion doses a year.
Its timeline for clinical trials is behind the likes of Moderna Inc, the University of Oxford in collaboration with AstraZeneca Plc, and an alliance of BioNTech and Pfizer Inc, whose projects all grabbed headlines by moving to human trials as early as March.
Sanofi has received financial backing from the United States and caused a stir in its home base of France after its British CEO Paul Hudson signalled that Europe was being too slow in supporting work on a vaccine, hinting U.S. patients might get any vaccine it develops first.
The EU is also seeking a deal with Sanofi, and has invited Britain to join its efforts to buy vaccines for the bloc. ($1 = 0.8011 pounds)


Clic here to read the story from its source.